Thermo Fisher Scientific Inc. (TMO) to Issue Quarterly Dividend of $0.43 on July 15th

Thermo Fisher Scientific Inc. (NYSE:TMO) declared a quarterly dividend on Wednesday, May 21st, RTT News reports. Stockholders of record on Friday, June 13th will be paid a dividend of 0.43 per share by the medical research company on Tuesday, July 15th. This represents a $1.72 annualized dividend and a dividend yield of 0.41%. The ex-dividend date of this dividend is Friday, June 13th.

Thermo Fisher Scientific has a dividend payout ratio of 7.0% indicating that its dividend is sufficiently covered by earnings. Analysts expect Thermo Fisher Scientific to earn $25.56 per share next year, which means the company should continue to be able to cover its $1.72 annual dividend with an expected future payout ratio of 6.7%.

Thermo Fisher Scientific Trading Up 1.5%

Shares of Thermo Fisher Scientific stock opened at $414.53 on Wednesday. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. The business has a fifty day simple moving average of $418.02 and a two-hundred day simple moving average of $494.38. Thermo Fisher Scientific has a 1 year low of $390.50 and a 1 year high of $627.88. The company has a market capitalization of $156.48 billion, a price-to-earnings ratio of 25.08, a P/E/G ratio of 2.99 and a beta of 0.78.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, beating analysts’ consensus estimates of $5.10 by $0.05. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. The business had revenue of $10.36 billion for the quarter, compared to analyst estimates of $10.23 billion. During the same quarter in the prior year, the business earned $5.11 EPS. Thermo Fisher Scientific’s quarterly revenue was up .2% on a year-over-year basis. Research analysts forecast that Thermo Fisher Scientific will post 23.28 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the company. Robert W. Baird lowered their price objective on Thermo Fisher Scientific from $603.00 to $573.00 and set an “outperform” rating on the stock in a research report on Thursday, April 24th. Royal Bank of Canada lowered their price target on shares of Thermo Fisher Scientific from $651.00 to $637.00 and set an “outperform” rating on the stock in a research report on Thursday, April 24th. Wells Fargo & Company cut their price objective on shares of Thermo Fisher Scientific from $580.00 to $570.00 and set an “overweight” rating for the company in a report on Thursday, April 24th. Stifel Nicolaus lowered their target price on shares of Thermo Fisher Scientific from $665.00 to $620.00 and set a “buy” rating on the stock in a report on Thursday, April 24th. Finally, UBS Group cut their price target on Thermo Fisher Scientific from $715.00 to $500.00 and set a “buy” rating for the company in a research note on Thursday, April 24th. Four equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. Based on data from MarketBeat.com, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and an average target price of $605.30.

Insiders Place Their Bets

In related news, EVP Gianluca Pettiti sold 300 shares of the firm’s stock in a transaction on Monday, April 28th. The stock was sold at an average price of $429.93, for a total transaction of $128,979.00. Following the sale, the executive vice president now owns 23,167 shares of the company’s stock, valued at $9,960,188.31. This trade represents a 1.28% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 0.33% of the company’s stock.

Hedge Funds Weigh In On Thermo Fisher Scientific

An institutional investor recently raised its position in Thermo Fisher Scientific stock. Revolve Wealth Partners LLC raised its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.2% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 491 shares of the medical research company’s stock after purchasing an additional 20 shares during the quarter. Revolve Wealth Partners LLC’s holdings in Thermo Fisher Scientific were worth $255,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.